Jul. 10 at 10:17 PM
$CNTX CT-202, which Context has yet to initiate Phase 1 for is a Nectin-4 TCE, whose rights were bought back from BioAtla 2 months ago after BioAtla sold its assets off in a fire sale. One could view this act as M&A/BD friendly behavior, but still premature.
$LLY
also is pursuing Nectin-4 as a target , but via ADC therapy. They reported good data for an this ADC last month.
This means CT-202 has some value now in a BO. If CT-95 can hit the mark, and the expanded data for CITM-76 has even higher ORR and continued safety, then the M&A discussion gets very interesting. Most oncology drugs dont make it past phase 1. So to have two phase 2 ready assets in CITM-76 and CT-202, and one phase 1 ready asset that has the potential to be complimentary to an ADC therapy of the same target in CT-202, is a big deal.
A lot of potential for this beaten down stock. A
$1.5 -
$2 share price before or after management reports CT-95 data in September to raise more cash would give them so much more leverage
